How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?

Clin Gastroenterol Hepatol. 2020 May;18(6):1291-1299. doi: 10.1016/j.cgh.2019.09.041. Epub 2019 Oct 4.

Abstract

The implementation of therapeutic drug monitoring (TDM) in the inflammatory bowel disease practice has evolved over the years. In the early days, the focus was merely on measuring and reporting drug concentrations. Later, these concentrations were considered in light of target concentrations that are related to clinical response. This not only allowed passively predicting a patient's future response, but it also triggered physicians and pharmacists to actively use the information to optimize the drug dosage to induce and maintain a clinical response in the future. Although reactive TDM, testing at time of loss of response, is widely accepted in practice, especially for anti-tumor necrosis factor antibodies, there are less data for the other monoclonal antibodies belonging to other classes. Besides reactive testing, there is a movement toward proactively adjusting biologic dosing to prevent loss of response, in keeping with the tight control philosophy of inflammatory bowel disease care. This review highlights the various assays available to measure drug concentrations and antidrug antibodies, as well as algorithmic approaches to TDM, the unmet needs and required studies to enable pharmacokinetics principles to be applied in the future.

Keywords: Inflammatory Bowel Disease (IBD).

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal
  • Drug Monitoring*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha